U.S. License Holder:
Pfenex Inc. / Alvogen
Date of License:
October-04-2019
Last Update:
Jan-23-2025
FDA-Approved Indications
BONSITY (teriparatide) is a parathyroid hormone analog (PTH 1-34) indicated for:
Treatment of postmenopausal women with osteoporosis at high risk for fracture;
Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture;
Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Livogiva (Theramex Ireland Limited /Pfenex) (August-2020)
Biosimilars Approved In South Korea
Bonsity® (Phambio) (November-2021)
